Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventional

Development of Acceptance and Commitment Therapy for Cancer Distress Among Rural and Urban Patients With Hepatobiliary Cancers (ACT-HBC)

NCT ID: NCT07124546Sponsor: Mayo ClinicLast updated: 2025-08-15

Summary

This clinical trial studies whether Acceptance and Commitment Therapy for patients with hepatobiliary cancers (ACT-HBC) can be used to help improve cancer distress. Patients with hepatobiliary cancer (HBC) often experience high levels of distress and reductions in quality of life. ACT-HBC is a behavioral intervention tailored to patients with HBC. It helps patients cope with difficult thoughts and emotions while staying connected to what matters most in life, which may be an effective way to improve cancer distress.

Arms & interventions

  • BehavioralAcceptance and Commitment Therapy

    Attend ACT-HBC telehealth group sessions

  • OtherQuestionnaire Administration

    Ancillary studies

  • OtherTelemedicine

    Attend ACT-HBC telehealth group sessions

Outcome measures

Primary

  • Patient satisfaction

    The Institute for Healthcare Improvement 10-point Likert scale (0-10) asks: "Would you recommend this program to your friends and family?" A score ≥ 7 indicates high individual satisfaction. Program satisfaction is achieved if 50% of individuals meet this cut-off.

    Time frame: At 8 weeks

  • Patient session attendance (Feasibility)

    Feasibility will be determined by the number of patients attending ≥ 4 sessions.

    Time frame: At 8 weeks

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * HBC diagnosis * Age \>= 18 years * Able to provide written informed consent * Verbally endorse cancer distress * Access to the internet * Read and write in English * Reside in the states of Iowa, Minnesota, or Wisconsin Exclusion Criteria: * Other psychological therapy that started =\< 2 months prior to prospective enrollment * Inability to actively participate in and learn from group therapy (e.g., active/uncontrolled psychotic symptoms, neurological condition, personality pathology) as determined by clinical judgement in Behavioral Medicine Program (BMP) consultation. Individual therapy or alternative group therapy will be offered to patients ineligible per this criterion * HBC remission

Study locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, 55905

Recruiting
Sofia Hammel · Contact
507-255-0760Hammel.Sofia@mayo.edu
Deanna Hofschulte · Contact
507-255-2972Hofschulte.Deanna@mayo.edu
Carrie A. Bronars, PhD, LP · Principal Investigator